Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Regulatory News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

Share Price is delayed by 15 minutes
Get Live Data
8.25    1.10 (14.86%)
Bid:
8.00
Ask:
8.50
Spread: 0.50 (6.25%)
Market Cap: £59.93m
POLB Live PriceLast checked at - London Stock Exchange

Intraday Poolbeg Pharma Share Chart

TR-1

23 Jul 2021 13:26

RNS Number : 3269G
Poolbeg Pharma PLC
23 July 2021
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Poolbeg Pharma PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Schroders PLC

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

21/07/2021

6. Date on which issuer notified (DD/MM/YYYY):

22/07/2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuervii

Resulting situation on the date on which threshold was crossed or reached

5.128388%

N/A

5.128388%

25,641,941

Position of previous notification (if

applicable)

N/A

N/A

N/A

 

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BKPG7Z60

25,641,941

5.128388%

SUBTOTAL 8. A

25,641,941

5.128388%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Schroders PLC

Schroder Administration Limited

Schroder Wealth Holdings Limited

Schroder & Co. Limited

Schroders plc

Schroder Administration Limited

Schroder International Holdings Limited

Schroder Investment Management Limited

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London

Date of completion

22/07/2021

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLDKNBBBBKDQOB
Date   Source Headline
26th May 20267:00 amRNSPre-IND Meeting with the FDA for POLB 001
13th May 20267:00 amRNSPOLB 001 poster to be presented at EHA 2026
11th May 20267:00 amRNSPOLB 001 CRS patent granted in Canada
7th May 20267:00 amRNSAnnual Report & AGM Notice
28th Apr 20267:00 amRNSResults for the year ended 31 December 2025
15th Apr 20267:00 amRNSMHRA grants CTA for the POLB 001 TOPICAL trial
31st Mar 20267:00 amRNSSignificant milestone for Poolbeg's IP portfolio
12th Mar 20267:00 amRNS-RAppointment of Dr Adrian Kilcoyne to SAB
9th Feb 20263:13 pmRNSNotification of Major Holdings
28th Jan 20267:00 amRNSPOLB 001 LPS Challenge Trial Paper Published
27th Jan 20262:30 pmRNSExercise of Options & Total Voting Rights
18th Dec 20257:00 amRNS-RLetter to Shareholders – 2025 a year of progress
8th Dec 20257:00 amRNS-RPOLB 001 to feature in CRS research programme
20th Nov 20257:00 amRNSPOLB 001 European Patent granted
29th Sep 20257:00 amRNSInterim Results for the six months to 30 June 2025
25th Sep 20257:00 amRNSPOLB 001 Phase 2a Trial Update
1st Jul 20254:24 pmRNSNotification of Major Holdings
26th Jun 20257:00 amRNSNotification of Major Holdings
25th Jun 20258:00 amRNSDirector/PDMR Shareholding
23rd Jun 20252:57 pmRNSResults of GM and AGM Meetings
27th May 20257:01 amRNSFDA Orphan Drug Designation granted for POLB 001
27th May 20257:00 amRNSAnnual Report, AGM Notice & Circular
23rd May 20257:00 amRNSResult of upsized oversubscribed BookBuild Offer
22nd May 20251:44 pmRNSIncrease of BookBuild Offer
20th May 202512:26 pmRNSResult of Placing and Notice of General Meeting
20th May 20257:02 amRNSProposed Retail Offer to raise up to £100,000
20th May 20257:01 amRNSProposed Fundraising to raise approximately £4.1M
20th May 20257:00 amRNSResults for the year ended 31 December 2024
27th Mar 20257:00 amRNS-RConference Participation in March & April 2025
20th Mar 20257:00 amRNS-RPOLB 001 Patent Granted in Korea
25th Feb 20258:50 amRNSForm 8.5 (EPT/NON-RI)
24th Feb 20258:48 amRNSForm 8.5 (EPT/NON-RI)
21st Feb 202511:53 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
21st Feb 20257:00 amRNSTermination of proposed combination with HOOKIPA
20th Feb 20258:06 pmGNWHOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
20th Feb 20259:03 amRNSForm 8.5 Poolbeg Pharma Plc
20th Feb 20258:53 amRNSForm 8.5 (EPT/NON-RI)
20th Feb 20257:49 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
19th Feb 202512:35 pmGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
18th Feb 20255:35 pmRNSHolding(s) in Company
18th Feb 20255:04 pmRNSForm 8.3 - Poolbeg Pharma plc
18th Feb 202510:17 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
17th Feb 202510:28 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
14th Feb 202510:25 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
14th Feb 20259:11 amRNSForm 8.5 Poolbeg Pharma Plc
13th Feb 202511:17 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
13th Feb 202510:30 amRNSForm 8.5 Poolbeg Pharma Plc
12th Feb 202510:52 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
12th Feb 20259:08 amRNSForm 8.5 Poolbeg Pharma Plc
11th Feb 20259:46 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.